Search
Menu
LPC/Photonics.com - Stay-Up-To-Date

Agendia

Facebook X LinkedIn Email
Agendia of Amsterdam, the Netherlands, has received market clearance from the FDA for its MammaPrint breast cancer diagnostic test. The device performs DNA microarray-based laboratory tests that measure the expression of 70 genes to predict the likelihood that the cancer will spread to another site. Information gained from the in vitro diagnostic multivariate index assays may help physicians plan follow-up treatment. The company had already been granted clearance to market the product in Europe.Read full article

Related content from Photonics Media



    Articles


    Products


    Photonics Handbook Articles


    White Papers


    Webinars


    Photonics Dictionary Terms


    Media


    Photonics Buyers' Guide Categories


    Companies
    Published: March 2007
    AgendiaBiophotonicsDNA microarray-based laboratory testsindex assaysNews & Features

    We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.